| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Endocrinology and Metabolism (K.M.C., K.W.L., N.H.K., S.G.K., D.S.C., S.H.B.) and Division of Cardiology (C.G.P., H.S.S., D.J.O.), Department of Internal Medicine, Korea University, Seoul, Korea
Address all correspondence and requests for reprints to: Dr. Kyung Mook Choi, Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital, 80 Guro-Dong, Guro-Gu, Seoul 152-050, Korea. E-mail: medica7{at}korea.ac.kr.
We examined the prevalence of impaired glucose metabolism and its association with inflammation and insulin resistance (IR) in acute myocardial infarction (AMI) patients without a previous diagnosis of diabetes. This prospective study enrolled 52 AMI patients, and 75-g oral glucose tolerance testing was performed on 30 patients at discharge and again 3 months later. We also measured serum adiponectin, high sensitive C-reactive protein, and IL-6 on both occasions. Data were compared with those of 30 type 2 diabetic patients without a history of AMI. Forty percent and 36.7% of AMI patients had impaired glucose tolerance (IGT) at discharge and at 3 months, respectively. The corresponding proportions for newly diagnosed diabetes are 33.0% and 30.0%. At discharge, AMI patients with IGT or diabetes showed higher high sensitive C-reactive protein and IL-6 levels compared with AMI patients with normal glucose tolerance or control type 2 diabetic patients. Furthermore, AMI patients with IGT or diabetes exhibited higher IR and lower serum adiponectin levels than AMI patients with normal glucose tolerance at 3 months after discharge. Previously undiagnosed diabetes and IGT are common in Korean patients with AMI. These glycometabolic abnormalities are associated with inflammation, IR, and serum adiponectin levels.
This article has been cited by other articles:
![]() |
M. Wallander, K. Malmberg, A. Norhammar, L. Ryden, and A. Tenerz Oral Glucose Tolerance Test: A Reliable Tool for Early Detection of Glucose Abnormalities in Patients With Acute Myocardial Infarction in Clinical Practice: A report on repeated oral glucose tolerance tests from the GAMI Study Diabetes Care, January 1, 2008; 31(1): 36 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jessani, G.Y.H. Lip, A. Barnett, and T. Millane The JBS-2 guidelines on prevention of cardiovascular disease in clinical practice: an opportunity missed QJM, February 1, 2007; 100(2): 121 - 124. [Full Text] [PDF] |
||||
![]() |
J. S. Krinsley and R. L. Jones Cost Analysis of Intensive Glycemic Control in Critically Ill Adult Patients Chest, March 1, 2006; 129(3): 644 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Knobler, M. Benderly, V. Boyko, S. Behar, Z. Matas, A. Rubinstein, I. Raz, and J. Wainstein Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose Eur. J. Endocrinol., January 1, 2006; 154(1): 87 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sattar and N. G. Forouhi Metabolic syndrome criteria: ready for clinical prime time or work in progress? Eur. Heart J., July 1, 2005; 26(13): 1249 - 1251. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |